Filter
10
Featured
Language
Document type
No document type
5
Guidelines
3
Studies & Reports
2
Countries / Regions
Cameroon
1
Authors & Publishers
World Health Organization WHO
4
World Health Organization
3
World Health Organisation (WHO)
2
, S. Eymard-Duvernay
1
A. Cournil
1
A. Phillips
1
E Clinical Medecine (Published by the Lancet)
1
Elsevier
1
et al.
1
G. F. Tchouwa
1
GHSA
1
L. Tayler
1
UCL
1
Publication Years
Category
Toolboxes
Drug resistance
10
Laboratory
5
ART Drug Resistance
4
EClinicalMedicine 1 (2018) 21–27 https://doi.org/10.1016/j.eclinm.2018.06.005 2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). EClinicalMedicine: journal homepage: https://www.jo... more
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ... more

Modelling the impact of HIVDR : the cost of inaction

A. Phillips World Health Organization; UCL (2016) C_WHO
WHO Considering programmatic implications of rising levels of HIV drug resistance: finalizing the Global Action Plan Webinars 12 13 Dec 2016
HIV drug resistance , Users Manual December 2017
12-13 December 2016 Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016

AMR and HIV Drug resistance

L. Tayler World Health Organization; GHSA (2016) C_WHO
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i... more
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les populations sous TAR. Bien que la résistance au DT... more
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este antirretrovírico en las poblaciones tratadas con esquemas que lo conti... more